Diagnosis of adenocarcinoma in prostate needle biopsy tissue

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.
Journal of Clinical Pathology (Impact Factor: 2.55). 02/2007; 60(1):35-42. DOI: 10.1136/jcp.2005.036442
Source: PubMed

ABSTRACT Prostate cancer is a major public health problem throughout the developed world. For patients with clinically localised prostate cancer, the diagnosis is typically established by histopathological examination of prostate needle biopsy samples. Major and minor criteria are used to establish the diagnosis, based on the microscopic appearance of slides stained using haematoxylin and eosin. Major criteria include an infiltrative glandular growth pattern, an absence of basal cells and nuclear atypia in the form of nucleomegaly and nucleolomegaly. In difficult cases, basal cell absence may be confirmed by immunohistochemical stains for high-molecular-weight cytokeratins (marked with antibody 34betaE12) or p63, which are basal cell markers. Minor criteria include intraluminal wispy blue mucin, pink amorphous secretions, mitotic figures, intraluminal crystalloids, adjacent high-grade prostatic intraepithelial neoplasia, amphophilic cytoplasm and nuclear hyperchromasia. Another useful diagnostic marker detectable by immunohistochemistry is alpha-methylacyl coenzyme A racemase (AMACR), an enzyme selectively expressed in neoplastic glandular epithelium. Cocktails of antibodies directed against basal cell markers and AMACR are particularly useful in evaluating small foci of atypical glands, and in substantiating a diagnosis of a minimal adenocarcinoma. Reporting of adenocarcinoma in needle biopsy specimens should always include the Gleason grade and measures of tumour extent in the needle core tissue. Measures of tumour extent are (1) number of cores positive for cancer in the number of cores examined, (2) percentage of needle core tissue affected by carcinoma and (3) linear millimetres of carcinoma present.

  • Source
    • "2002 ; Jiang et al . 2005 ; Humphrey 2007 ) . Similarly , prostate cancer arising in many mouse models displays a relatively luminal phenotype ( Kim et al . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite much recent progress, prostate cancer continues to represent a major cause of cancer-related mortality and morbidity in men. Since early studies on the role of the androgen receptor that led to the advent of androgen deprivation therapy in the 1940s, there has long been intensive interest in the basic mechanisms underlying prostate cancer initiation and progression, as well as the potential to target these processes for therapeutic intervention. Here, we present an overview of major themes in prostate cancer research, focusing on current knowledge of principal events in cancer initiation and progression. We discuss recent advances, including new insights into the mechanisms of castration resistance, identification of stem cells and tumor-initiating cells, and development of mouse models for preclinical evaluation of novel therapuetics. Overall, we highlight the tremendous research progress made in recent years, and underscore the challenges that lie ahead.
    Genes & development 09/2010; 24(18):1967-2000. DOI:10.1101/gad.1965810 · 12.64 Impact Factor
  • Source
    • "However, the definitive diagnosis of cancer is based on histological assessment of the needle biopsy tissue material [23]. Although DRE allows the clinician to 'feel' the prostate it has a poor sensitivity, and typically only allows the detection of relatively large tumours which usually represent locally advanced disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer-related deaths in men. Currently, serum prostate-specific antigen (PSA) is the only biomarker widely used in the diagnosis and management of patients with PCa. However, PSA lacks diagnostic sensitivity and specificity, leading to false-negative and false-positive test results. PSA cannot distinguish indolent from aggressive disease, leading to many patients being over-treated with associated side-effects. Furthermore, PSA is unable to identify which tumors are likely to become unresponsive to treatment at an early stage. Thus, there is an urgent need for clinically validated biomarkers which will improve the diagnosis and management of PCa. Given the heterogeneity of PCa it is likely that a panel of biomarkers will be required. In the quest for PCa biomarkers, a wide range of samples including urine, serum, tissues, and cell lines have been studied using proteomic approaches such as 2-DE, SELDI-TOF, SILAC, ICAT, iTRAQ, and MALDI-IMS. The value of these technologies, and other emerging platforms such as selected reaction monitoring (SRM) and multiple reaction monitoring (MRM), are discussed in the context of biomarker discovery, validation and addressing the "bottle-necks" that exist prior to clinical translation. Copyright © 2009 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.
    PROTEOMICS - CLINICAL APPLICATIONS 02/2009; 3(2):197 - 212. DOI:10.1002/prca.200800154 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A fuzzy neural relational model of software quality derived from the McCall hierarchical software quality measurement framework (HSQF), is introduced. The HSQF has three fundamental levels (factors→criteria→metrics) which has a rather natural generalization in the context of fuzzy sets. Vectors of factors, criteria, and metrics are treated as fuzzy sets. On each level, fuzzy objects (fuzzy set and fuzzy relation) are introduced. A learning algorithm is proposed to calibrate the relations at the topmost levels of the software quality model. A learning scenario and detailed learning formulas are given. A brief illustration of the model is also given
    Fuzzy Systems Proceedings, 1998. IEEE World Congress on Computational Intelligence., The 1998 IEEE International Conference on; 06/1998
Show more


1 Download
Available from